ZA958762B - Medicinal and/or nutritional microcapsules for oral administration - Google Patents

Medicinal and/or nutritional microcapsules for oral administration

Info

Publication number
ZA958762B
ZA958762B ZA958762A ZA958762A ZA958762B ZA 958762 B ZA958762 B ZA 958762B ZA 958762 A ZA958762 A ZA 958762A ZA 958762 A ZA958762 A ZA 958762A ZA 958762 B ZA958762 B ZA 958762B
Authority
ZA
South Africa
Prior art keywords
medicinal
oral administration
microcapsules
nutritional
nutritional microcapsules
Prior art date
Application number
ZA958762A
Other languages
English (en)
Inventor
Pierre Autant
Jean-Philippe Selles
Gerard Soula
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9468196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA958762(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of ZA958762B publication Critical patent/ZA958762B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA958762A 1994-10-18 1995-10-17 Medicinal and/or nutritional microcapsules for oral administration ZA958762B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9412759A FR2725623A1 (fr) 1994-10-18 1994-10-18 Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os

Publications (1)

Publication Number Publication Date
ZA958762B true ZA958762B (en) 1996-05-09

Family

ID=9468196

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA958762A ZA958762B (en) 1994-10-18 1995-10-17 Medicinal and/or nutritional microcapsules for oral administration

Country Status (14)

Country Link
US (1) US6022562A (de)
EP (1) EP0709087B1 (de)
JP (1) JP4053589B2 (de)
AR (1) AR022930A2 (de)
AT (1) ATE188117T1 (de)
AU (1) AU3807795A (de)
BR (2) BRPI9509286B8 (de)
CA (1) CA2160762C (de)
DE (1) DE69514192T2 (de)
ES (1) ES2140641T3 (de)
FR (1) FR2725623A1 (de)
IL (1) IL115646A (de)
WO (1) WO1996011675A2 (de)
ZA (1) ZA958762B (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
FI102944B (fi) * 1996-06-19 1999-03-31 Nokia Mobile Phones Ltd Potilaan hoitolaite sekä hoitojärjestelmä
AU751066B2 (en) 1997-12-08 2002-08-08 Nycomed Gmbh Novel administration form comprising an acid-labile active compound
ES2174600T3 (es) * 1998-04-09 2002-11-01 Eurand Int Microcapsula humectante compuesta de un medicamento encapsulado por etilcelulosa.
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
AU3400501A (en) * 2000-02-28 2001-09-12 Vectura Ltd Improvements in or relating to the delivery of oral drugs
MXPA02012795A (es) * 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
GB0026512D0 (en) * 2000-10-30 2000-12-13 Benfell S Ltd Protective beacon
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US6833377B2 (en) 2001-02-05 2004-12-21 Gevys Pharmaceuticals Ltd. Composition and method for potentiating drugs
US20050192220A1 (en) * 2001-02-05 2005-09-01 Gevys Pharmaceuticas Ltd. Composition and method for potentiating drugs
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
MXPA04006909A (es) * 2002-01-15 2005-04-19 Teva Pharma Solidos cristalinos de carvedilol y procesos para su preparacion.
FR2837100B1 (fr) * 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
FR2843881B1 (fr) * 2002-09-02 2006-06-02 Flamel Tech Sa Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
FR2843880B1 (fr) * 2002-09-02 2006-06-02 Flamel Tech Sa Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
EP1492511B3 (de) * 2002-04-09 2012-05-02 Flamel Technologies Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
CN100577164C (zh) * 2002-04-09 2010-01-06 弗拉梅技术公司 可改进释放阿莫西林的微囊含水混悬液形式的口服药物制剂
US7008979B2 (en) * 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US20040208936A1 (en) * 2002-07-22 2004-10-21 Roland Chorin Novel compositions
FR2842735B1 (fr) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
JP2006521366A (ja) * 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
CN1819821B (zh) * 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US8734850B2 (en) 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
EP1750717B1 (de) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Pharmazeutische zusammensetzungen mit kontrollierter freisetzung und verbesserter bioverfügbarkeit
US20070122488A1 (en) * 2004-02-25 2007-05-31 Erich Windhab Multi-functional microcapsules and method and device for manufacturing same
DE102004029732A1 (de) 2004-06-21 2006-01-19 Basf Ag Hilfsmittel enthaltend Cyclohexanpolycarbonsäurederivate
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
AU2005280058B2 (en) * 2004-08-25 2010-09-02 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
CA2581816A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
EP2965751A1 (de) 2004-10-08 2016-01-13 Forward Pharma A/S Gesteuerte freisetzung von pharmazeutischen zusammensetzungen mit fumarinsäureester
FR2878159B1 (fr) * 2004-11-24 2008-10-17 Flamel Technologies Sa Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
JP2008530185A (ja) * 2005-02-21 2008-08-07 フラメル・テクノロジー ロサルタンの経口医薬剤形態
FR2882259A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
US20100009005A1 (en) * 2005-05-24 2010-01-14 Flamel Technologies ,S.A. Novel acetysalicylic acid formulations
US20070166378A1 (en) * 2005-06-09 2007-07-19 Flamel Technologies, Inc. Oral ribavirin pharmaceutical compositions
US20070043099A1 (en) * 2005-06-09 2007-02-22 Igor Lifshitz Crystalline forms of carvedilol and processes for their preparation
WO2006131790A2 (en) * 2005-06-09 2006-12-14 Flamel Technologies Oral ribavirin pharmaceutical composition
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007052436A1 (ja) * 2005-10-31 2007-05-10 Niigata University マイクロカプセル及びその製造方法
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
ES2374963T3 (es) 2006-01-05 2012-02-23 Essentialis, Inc. Sales de agentes de apertura del canal de potasio dependiente de atp y usos de las mismas.
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
EP2007360B1 (de) * 2006-04-03 2014-11-26 Isa Odidi Abgabevorrichtung mit organosol-beschichtung und kontrollierter freisetzung
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US8022094B2 (en) * 2006-06-28 2011-09-20 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
US20080207726A1 (en) * 2007-02-26 2008-08-28 Santiago Ini Process for the purification of carvedilol or its salts thereof
CA2683409A1 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
ES2963291T3 (es) * 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
US20100239665A1 (en) * 2007-05-01 2010-09-23 Ivan Coulter Pharmaceutical nimodipine compositions
CA2692160A1 (en) * 2007-07-02 2009-01-08 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
BRPI0912842A8 (pt) * 2008-05-20 2019-01-29 Cerenis Therapeutics Holding composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
CN102481276A (zh) 2009-04-20 2012-05-30 埃尔舍利克斯治疗公司 基于化学感受受体配体的治疗法
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
EP2432455B1 (de) 2009-05-18 2014-11-12 Sigmoid Pharma Limited Zusammensetzung mit öltropfen
FR2945945B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Procede de preparation de particules creuses et leurs applications
FR2945947B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
CA2770570A1 (en) 2009-08-12 2011-02-17 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
WO2011119839A1 (en) 2010-03-24 2011-09-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
CN104220875A (zh) 2010-10-19 2014-12-17 埃尔舍利克斯治疗公司 基于化学感应受体配体的治疗
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
MX2013007884A (es) 2011-01-07 2013-09-13 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
US8900631B2 (en) 2011-04-28 2014-12-02 Health Science Funding, LLC Dosage form to increase prasterone bioavailability
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (de) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natürliche kombinationshormonersatzformulierungen und therapien
CN110693867A (zh) 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
AU2012363873B2 (en) 2012-01-06 2017-11-23 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
EP2819675A4 (de) 2012-02-27 2015-07-22 Essentialis Inc Salze von kalium-atp-kanalöffnern und verwendungen davon
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
EP2872127A1 (de) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Zusammensetzungen mit statinen, biguaniden und weiteren mitteln zur verringerung des herz-kreislauf-risikos
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2015008625A (es) 2013-01-05 2015-09-23 Elcelyx Therapeutics Inc Composicion de liberacion demorada que comprende biguanida.
DK3300015T3 (da) 2013-03-12 2019-11-18 Panacea Biomatx Inc System til fremstilling af individuelle formuleringer til individer
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US10172794B2 (en) 2013-12-13 2019-01-08 Biogen Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016046817A1 (en) * 2014-09-24 2016-03-31 Vital Beverages Global Inc. Compositions and methods for selective gi tract delivery
PL3215127T3 (pl) 2014-11-07 2021-05-17 Sublimity Therapeutics Limited Kompozycje zawierające cyklosporynę
CA3210794A1 (en) 2014-11-14 2016-05-19 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
EP3310341A1 (de) 2015-06-17 2018-04-25 Biogen MA Inc. Dimethylfumaratteilchen und pharmazeutische zusammensetzungen daraus
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CN106943356B (zh) * 2017-05-10 2019-11-08 武汉人福药业有限责任公司 一种泛昔洛韦缓释颗粒剂及其制备方法
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
CN112004520A (zh) 2017-12-18 2020-11-27 特瑞斯制药公司 包括具有触发脉冲药物释放的胃内滞留筏形成系统的调节释放药物粉末组合物
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US12029719B2 (en) 2021-04-16 2024-07-09 Allen Morgan Compounds comprising cannabinoids and other natural ingredients for alieving premenstrual, menstrual and menopausal symptoms
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
LU85943A1 (fr) * 1985-06-12 1987-01-13 Galephar Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
IT1227899B (it) * 1988-12-23 1991-05-14 Poli Ind Chimica Spa Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation

Also Published As

Publication number Publication date
AU3807795A (en) 1996-05-06
FR2725623A1 (fr) 1996-04-19
ATE188117T1 (de) 2000-01-15
DE69514192D1 (de) 2000-02-03
WO1996011675A2 (fr) 1996-04-25
BRPI9509286B8 (pt) 2019-12-17
EP0709087B1 (de) 1999-12-29
US6022562A (en) 2000-02-08
DE69514192T2 (de) 2000-07-13
ES2140641T3 (es) 2000-03-01
AR022930A2 (es) 2002-09-04
JP4053589B2 (ja) 2008-02-27
FR2725623B1 (de) 1997-02-21
IL115646A0 (en) 1996-01-19
IL115646A (en) 2000-07-16
WO1996011675A3 (fr) 1996-06-20
JPH10509427A (ja) 1998-09-14
BR9509286A (pt) 1997-10-14
EP0709087A1 (de) 1996-05-01
CA2160762C (fr) 2004-12-21
CA2160762A1 (fr) 1996-04-19

Similar Documents

Publication Publication Date Title
ZA958762B (en) Medicinal and/or nutritional microcapsules for oral administration
EP0919228A4 (de) Kapseln für orale zubereitungen und kapselzubereitungen zur oralen verabreichung
PL322579A1 (en) 2-methyl-thiene-benzodiazeoin prparation for oral administration
IL117041A0 (en) Oral pharmaceutical dosage form
NZ321576A (en) 6-imidazol-1-ylmethyl-2-oxo-quinoline derivatives and medicaments
GB9407386D0 (en) Pharmaceutical formulation
GB9402203D0 (en) Pharmaceutical formulation
HUP9903407A3 (en) Oral pharmaceutical preparation containing ibandronat
IL112521A0 (en) Pharmaceutical formulation
HUT75246A (en) Soft gelatin pharmaceutical dosage form
PL334439A1 (en) Rapidly liberating and taste masking pharmaceutical administration form
ZA956915B (en) Glycinamide derivatives processes for their preparation and medicines containing them
GB9405856D0 (en) Pharmaceutical formulation
GB9416599D0 (en) Pharmaceutical formulation
PL307469A1 (en) Preparation for oral administration
GB9408053D0 (en) Pharmaceutical preparation
GB9601186D0 (en) Administration of Drugs
HUP9602977A3 (en) Arylpiperidine and arylpiperazine derivatives and drugs containing the same
ZA951789B (en) Pharmaceutical materials and methods of administration
ZA934523B (en) Medicinal preparation
GB9418550D0 (en) Drug formulation
GB9408369D0 (en) Oral administration of protein drugs
GB9418414D0 (en) Long-term administration of drugs
IL110983A0 (en) Pharmaceutical compounds and their preparation
ZA952013B (en) Pharmaceutical preparation